Kidney shield: diabetes Drug's hidden powers revealed?

NCT ID NCT05507892

Ongoing Knowledge-focused Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how canagliflozin (Invokana), a diabetes drug, protects the kidneys in people with type 2 diabetes. Researchers will use advanced imaging, kidney biopsies, and function tests to uncover the mechanisms. The trial involves 45 adults and aims to explain the drug's kidney-protective effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: canagliflozin (Invokana)
What this could lead to: If successful, this could reveal exactly how canagliflozin protects the kidneys, potentially leading to better treatments for diabetic kidney disease.
What could go wrong: This is a small, early-phase study focused on understanding mechanisms, not proving clinical benefit. Results may not lead to new treatments or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC KIDNEY DISEASE TYPE 2 DIABETES

Contacts and locations

Locations

University of Colorado Denver

Aurora, Colorado, 80045, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.